Delivery of drug-loaded microbubbles and disruption of blood-brain barrier by focused ultrasound in a xenograft rat glioma model

Author(s):  
Chien-Yu Ting ◽  
Ching-Hsiang Fan ◽  
Hao-Li Liu ◽  
Tzu-Chen Yen ◽  
Kuo-Chen Wei ◽  
...  
2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii286-iii286
Author(s):  
Zachary Englander ◽  
Hong-Jian Wei ◽  
Antonios Pouliopoulos ◽  
Pavan Upadhyayula ◽  
Chia-Ing Jan ◽  
...  

Abstract BACKGROUND Drug delivery remains a major obstacle in DIPG, as the blood brain barrier (BBB) limits the penetration of systemic therapies to the brainstem. Focused ultrasound (FUS) is an exciting new technology that, when combined with microbubbles, can open the BBB permitting the entry of drugs across the cerebrovasculature. Given that the utility of FUS in brainstem tumors remains unknown, the purpose of our study was to determine the safety and feasibility of this technique in a murine pontine glioma model. METHODS A syngeneic orthotopic model was established by stereotactic injection of PDGF-B+PTEN-/-p53-/- murine glioma cells (10,000/1ul) into the pons of B6 albino mice. A single-element, spherical-segment FUS transducer (center frequency=1.5MHz) driven by a function generator through a power amplifier (acoustic pressure=0.7MPa) was used with concurrent intravenous microbubble injection (FUS+MB) to sonicate the tumor on post-injection day 14. BBB opening was confirmed with gadolinium-enhanced MRI and Evans blue. Kondziela inverted screen (KIS) testing was completed to measure motor function. Mice were either immediately sacrificed for histopathological assessment or serially monitored for survival. RESULTS In mice treated with FUS (n=11), there was no measured deficit in KIS testing. Additionally, the degree of intra-tumoral hemorrhage and inflammation on H&E in control (n=5) and treated mice (n=5) was similar. Lastly, there was no difference in survival between the groups (control, n=6, median=26 days; FUS, n=6, median=25 days, p>0.05). CONCLUSION FUS+MB is a safe and feasible technique to open the BBB in a preclinical pontine glioma model.


1985 ◽  
Vol 67 (1-2) ◽  
pp. 96-102 ◽  
Author(s):  
P. A. Stewart ◽  
K. Hayakawa ◽  
E. Hayakawa ◽  
C. L. Farrell ◽  
R. F. Del Maestro

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Zachary K. Englander ◽  
Hong-Jian Wei ◽  
Antonios N. Pouliopoulos ◽  
Ethan Bendau ◽  
Pavan Upadhyayula ◽  
...  

AbstractDrug delivery in diffuse intrinsic pontine glioma is significantly limited by the blood-brain barrier (BBB). Focused ultrasound (FUS), when combined with the administration of microbubbles can effectively open the BBB permitting the entry of drugs across the cerebrovasculature into the brainstem. Given that the utility of FUS in brainstem malignancies remains unknown, the purpose of our study was to determine the safety and feasibility of this technique in a murine pontine glioma model. A syngeneic orthotopic model was developed by stereotactic injection of PDGF-B+PTEN−/−p53−/− murine glioma cells into the pons of B6 mice. A single-element, spherical-segment 1.5 MHz ultrasound transducer driven by a function generator through a power amplifier was used with concurrent intravenous microbubble injection for tumor sonication. Mice were randomly assigned to control, FUS and double-FUS groups. Pulse and respiratory rates were continuously monitored during treatment. BBB opening was confirmed with gadolinium-enhanced MRI and Evans blue. Kondziela inverted screen testing and sequential weight lifting measured motor function before and after sonication. A subset of animals were treated with etoposide following ultrasound. Mice were either sacrificed for tissue analysis or serially monitored for survival with daily weights. FUS successfully caused BBB opening while preserving normal cardiorespiratory and motor function. Furthermore, the degree of intra-tumoral hemorrhage and inflammation on H&E in control and treated mice was similar. There was also no difference in weight loss and survival between the groups (p > 0.05). Lastly, FUS increased intra-tumoral etoposide concentration by more than fivefold. FUS is a safe and feasible technique for repeated BBB opening and etoposide delivery in a preclinical pontine glioma model.


1992 ◽  
Vol 12 (2) ◽  
pp. 174-179 ◽  
Author(s):  
Ying Ji ◽  
Diana L. Walstad ◽  
J. Tony Brown ◽  
Stephen K. Powers

Author(s):  
D. Schuepbach ◽  
P. R. Gavin ◽  
L. G. Salford ◽  
C. Ceberg ◽  
H. Fankhauser

2021 ◽  
Vol 7 (6) ◽  
pp. eabd0772
Author(s):  
Ko-Ting Chen ◽  
Wen-Yen Chai ◽  
Ya-Jui Lin ◽  
Chia-Jung Lin ◽  
Pin-Yuan Chen ◽  
...  

Focused ultrasound (FUS) in the presence of microbubbles can transiently open the blood-brain barrier (BBB) to increase therapeutic agent penetration at the targeted brain site to benefit recurrent glioblastoma (rGBM) treatment. This study is a dose-escalating pilot trial using a device combining neuronavigation and a manually operated frameless FUS system to treat rGBM patients. The safety and feasibility were established, while a dose-dependent BBB-opening effect was observed, which reverted to baseline within 24 hours after treatment. No immunological response was observed clinically under the applied FUS level in humans; however, selecting a higher level in animals resulted in prolonged immunostimulation, as confirmed preclinically by the recruitment of lymphocytes into the tumor microenvironment (TME) in a rat glioma model. Our findings provide preliminary evidence of FUS-induced immune modulation as an additional therapeutic benefit by converting the immunosuppressive TME into an immunostimulatory TME via a higher but safe FUS dosage.


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Yaoheng Yang ◽  
Xiaohui Zhang ◽  
Dezhuang Ye ◽  
Richard Laforest ◽  
Jeffrey Williamson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document